The Companies to Watch column spotlights small, entrepreneurial biopharma companies that are developing their own products (not just a platform) with little or no press coverage to date, and offering an interesting story involving useful business lessons.
With 24 employees, Paris-based Abivax is in Phase 2 clinical development of its lead drug candidate, which is a potential functional cure for HIV infection. It has also recently spawned an early clinical program in inflammatory bowel disease (IBD).
Madrigal Pharmaceuticals is taking on NASH and other liver diseases by targeting the thyroid hormone beta receptor. The company expects to begin seeing top line Phase 2 trial results in late 2017, with more released in 2018.
By early 2016, Arena’s board decided to remake the company, beginning with new management and a new strategy. Since then, the company has evolved back to a core drug development platform.
ProMIS Neurosciences believes inaccurate targeting of mAbs is to blame, in fact, for lack of progress against Alzheimer’s disease.
Outside skepticism about GeNeuro’s scientific concept has made fund-raising even harder than usual for a startup. But the Swiss company has found considerable support in Europe.
Frequency Therapeutics is an early-stage developer of small molecule drugs to activate “progenitor cells” and restore healthy tissue. Its lead program is in treating hearing loss by regenerating sensory cells in the inner ear, for which it is planning a Phase 1 trial to launch in mid-2018.
To heal the wounds — maintaining and restoring cellular homeostasis with novel secretomes.
An anti-infective immunotherapy developer on a mission to replace antibiotics with engineered antibodies and novel mechanisms.
In Phase 3 with an innovatively delivered drug to treat a deadly complication of ruptured brain aneurysm.
There is no grand plan for a whole year of Companies to Watch (CtW). Each month, a single candidate makes the cut for a single column. Nevertheless, patterns emerge among the CtWs as the year progresses and come into focus as it ends.
Three top biopharmaceutical executives share their ideas on what bio clusters biopharmaceutical executives should be paying attention to for 2018. In addition, insights are provided on other future potential bio hot spots.
Five top biopharmaceutical executives share their thoughts on Big Data, industry trends, personalized medicine, and more in preparing you for what to expect in 2018 – and beyond.
Five female biopharmaceutical industry CEOs share exclusive insights on what to expect for 2018 and beyond.
A behind the scenes look into the educational planning for the 2018 BIO International Convention in Boston.
In the December 2017 issue’s article, “The Women of Biopharma — Will They Gain or Lose Ground in 2018?” we summarize the responses of those who chose to contribute as panelists in a “virtual roundtable” discussion. Here, as promised, we are posting their written responses in full.